RxDoctor Payments Data

Ly Hoang Roberts, MD

Urogynecology and Reconstructive Pelvic Surgery · Cleveland, OHNPI 1689051674

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (43.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 92.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $10,146 and has fallen 58.6% since, to $4,196 in 2025.

$23,220in general payments, 2019–2025

Across 71 payments — averaging $327.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$21K
  • Intuitive Surgical$841
  • Axonics, Inc.$259
  • Boston Scientific$239
  • Astellas Pharma US Inc$183
  • Urovant Sciences Inc$125
  • plus $212 from 3 others

What the payments were for

  • Speaking & faculty fees$8,29336%
  • Grants$10,00043%
  • Travel & lodging$7973%
  • Food & beverage$3,94717%
  • Education$1831%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,220 in reported general payments places this provider in the 85th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.

See all urogynecology and reconstructive pelvic surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$63,363
Medicare patients
257
Services billed
677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron88$49,967
GemtesaVibegron49$30,815
Mirabegron ErMirabegron11$6,266
Trospium Chloride49$2,904
Estradiol53$2,778
Trospium Chloride ErTrospium Chloride25$2,004
Solifenacin Succinate20$1,304
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst31$581
Oxybutynin Chloride ErOxybutynin Chloride28$461
Cephalexin36$212
Tamsulosin Hcl15$113
Sodium ChlorideSodium Chloride Irrig Solution14$97
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$183$49,96788 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.

Other urogynecology and reconstructive pelvic surgery in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →